ClinicalTrials.gg
CompletedNCT00606320Updated Feb 12, 2014Results posted

A Multicenter, Investigative Study of the Safety and Efficacy of Extended Administration of Aripiprazole in Combination With Mood Stabilizer for the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode

A Phase 3 interventional study of Aripiprazole in Bipolar I Disorder, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 12 sites in 4 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-02-12.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
59
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

To assess the safety and efficacy of long-term administration of aripiprazole by performing extended administration of aripiprazole in combination with mood stabilizer (lithium or valproate) in an unblinded manner to those patients who completed the preceding multicenter, double-blind, placebo-controlled, parallel group-comparison trial of aripiprazole in patients with bipolar disorder experiencing a manic or mixed episode (Study 031-06-003, hereafter "Study 003") but whose condition worsened or remained unchanged or who discontinued Study 003 between Day 14 and Day 21 due to lack of drug efficacy.

02

Conditions studied

  • Bipolar I Disorder
03

In context

Lead sponsor

Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Trial subjects will be men and women of age 18 or above and below the age of 65 who will not be turning 65 during the trial.
  • Subjects have the ability to understand and to provide to the examination, observation, and evaluation processes specified in this protocol, and have signed the informed consent form based on a full understanding of the trial.
  • Subjects who meet criteria for manic or mixed episodes and have been diagnosed as having "296.4x Bipolar I Disorder in which the most recent episode was manic" or "296.6x Bipolar I Disorder in which the most recent episode was mixed"
  • Subjects who were enrolled in and have completed or withdrawn from Study 003 and who meet the following criteria

    • Subjects who show exacerbation of condition or no change in condition: Those subjects who completed Study 003, and whose score for CGI-BP Change from preceding phase (mania) on Day 21 (completion of Study 003) was between 5 (Minimally worse) and 7 (Very much worse) (subjects showing exacerbation of condition), or whose score was 4 (No change) (subjects showing no change in condition)
    • Subjects who discontinued due to lack of drug efficacy: Those subjects who discontinued Study 003 between Day 14 and Day 21, for whom the reason of withdrawal was lack of drug efficacy, and whose score for CGI-BP Change from preceding phase (mania) was between 5 (Minimally worse) and 7 (Very much worse)

Exclusion criteria

Exclusion Criteria:

  • Subjects presenting with a clinical picture and/or history that is consistent with a diagnosis of:

    • Delirium, dementia, amnestic disorder, or other cognitive disorders
    • Schizophrenia or other psychotic disorder
    • Personality disorder
  • Subjects with psychotic symptoms that are clearly due to another general medical condition or direct physiological effects of a substance
  • Subjects who represent a significant risk of committing suicide
  • Subjects known to have a complication of allergy to aripiprazole, other quinolinone-skeleton compounds, lithium, or valproate
  • Subjects with a complication of neuroleptic malignant syndrome
  • Subjects in a state of physical exhaustion accompanied by such conditions as dehydration or malnutrition
  • Subjects with a complication of paralytic ileus
  • Subjects with a complication of organic brain disorder or convulsive disorder, such as epilepsy
  • Subjects with a complication of diabetes
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    Aripiprazole

    Drug: Aripiprazole

Interventions

  • oral, 24mg(4 tablets)/day

    Also known as: OPC-14597

06

What researchers measure

Primary outcomes

  1. Young Mania Rating Scale (YMRS)

    YMRS is composed of 11 evaluation items with 5 rating levels each. Items rated on a scale of 0 to 4 (comprising 5 rating levels of one point each) are 1) levated mood, 2) increased motor activity/energy, 3) sexual interest, 4) sleep, 7) language-thought disorder, 10) appearance, and 11) insight. Items rated on a scale of 0 to 8 (comprising 5 rating levels of two points each) are 5) irritability, 6) speech (rate and amount), 8) content, and 9) disruptive-aggressive behavior. YMRS ranges from 0 (best possible outcome) to 60 (worst possible outcome). Using LOCF datasets, descriptive statistics of actual values for changes of YMRS total scores from baseline (Day 1 of preceding study) to endpoint (Day 154) was calculated.

    Time frame: baseline (Day 1 of preceding study), Day 154 or at discontinuation

Secondary outcomes

  1. Clinical Global Impression - Bipolar Version (CGI-BP) Severity of Illness (Mania)

    CGI-BP severity of illness is a scale for overall evaluation of the severity of bipolar disorder; it comprises 3 components-mania, depression, and overall bipolar illness. CGI-BP severity of illness score (mania) ranges form 1 (normal, not ill) to 7 (very severely ill). Using LOCF datasets, descriptive statistics of actual values for change of CGI-BP severity of illness score (mania) from baseline (Day 1 of preceding study) to endpoint (Day 154) was calculated for each treatment group.

    Time frame: Baseline (Day 1 of preceding study) , Day 154 or at discontinuation

07

Results

Posted Feb 12, 2014

Participant flow

Participant flow — Overall Study
MilestoneAripiprazple
Started59
Completed22
Not completed37
Withdrew: Adverse event3
Withdrew: Lack of efficacy5
Withdrew: Physician decision7
Withdrew: Protocol violation8
Withdrew: Withdrawal by subject10
Withdrew: Progression to depressive phase4

Outcome measures

PrimaryYoung Mania Rating Scale (YMRS)

YMRS is composed of 11 evaluation items with 5 rating levels each. Items rated on a scale of 0 to 4 (comprising 5 rating levels of one point each) are 1) levated mood, 2) increased motor activity/energy, 3) sexual interest, 4) sleep, 7) language-thought disorder, 10) appearance, and 11) insight. Items rated on a scale of 0 to 8 (comprising 5 rating levels of two points each) are 5) irritability, 6) speech (rate and amount), 8) content, and 9) disruptive-aggressive behavior. YMRS ranges from 0 (best possible outcome) to 60 (worst possible outcome). Using LOCF datasets, descriptive statistics of actual values for changes of YMRS total scores from baseline (Day 1 of preceding study) to endpoint (Day 154) was calculated.

Time frame:
baseline (Day 1 of preceding study), Day 154 or at discontinuation
Reported as:
Mean · scores on a scale
Young Mania Rating Scale (YMRS)
scores on a scaleAripiprazple
Young Mania Rating Scale (YMRS)-18.3 ± 12.71
SecondaryClinical Global Impression - Bipolar Version (CGI-BP) Severity of Illness (Mania)

CGI-BP severity of illness is a scale for overall evaluation of the severity of bipolar disorder; it comprises 3 components-mania, depression, and overall bipolar illness. CGI-BP severity of illness score (mania) ranges form 1 (normal, not ill) to 7 (very severely ill). Using LOCF datasets, descriptive statistics of actual values for change of CGI-BP severity of illness score (mania) from baseline (Day 1 of preceding study) to endpoint (Day 154) was calculated for each treatment group.

Time frame:
Baseline (Day 1 of preceding study) , Day 154 or at discontinuation
Reported as:
Mean · scores on a scale
Clinical Global Impression - Bipolar Version (CGI-BP) Severity of Illness (Mania)
scores on a scaleAripiprazple
Clinical Global Impression - Bipolar Version (CGI-BP) Severity of Illness (Mania)-2.4 ± 1.76

Adverse events

Collected over 22 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aripiprazole—2/56 (3.6%)37/56 (66.1%)
Most frequent serious events
Most frequent serious events
EventAripiprazole
HepatitisHepatobiliary disorders1/56
HeadacheNervous system disorders1/56
ManiaPsychiatric disorders1/56
Most frequent other events
Showing 10 of 17
Most frequent other events
EventAripiprazole
Weight IncreasedInvestigations16/56
AkathisiaNervous system disorders12/56
TremorNervous system disorders10/56
SomnolenceNervous system disorders8/56
InsomniaPsychiatric disorders8/56
NasopharyngitisInfections and infestations5/56
HeadacheNervous system disorders5/56
ConstipationGastrointestinal disorders4/56
Salivary HypersecretionGastrointestinal disorders4/56
VomitingGastrointestinal disorders4/56

Baseline characteristics

Full Analysis Population(FAS):Excluding the following subjects from the randomized subjects: * 3 subjects with GCP violation * 1 subject whose post dose efficacy were not available

Age, Continuous
Age, Continuous(years)Arupiprazole
Mean34.5 ± 12.45
Age, Categorical
Age, Categorical(Participants)Arupiprazole
<=18 years3
Between 18 and 65 years52
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)Arupiprazole
Female28
Male27
Region of Enrollment
Region of Enrollment(participants)Arupiprazole
Taiwan5
China17
Japan11
Malaysia6
Indonesia4
Philippines12
08

Study locations

12 sites
  • HongKong, China
  • Chubu region, Japan
  • Chugoku region, Japan
  • Hokkaido region, Japan
  • Hokuriku region, Japan
  • Kanto region, Japan
  • Kinki region, Japan
  • Kyushu region, Japan
  • Shikoku region, Japan
  • Tohoku region, Japan
  • Seoul, Korea, Republic of
  • Taipei, Taiwan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2014, 3 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2008
First posted
Feb 1, 2008
Start
Jan 2008
Primary completionActual
Nov 2010
CompletionActual
Nov 2010
Results first posted
Feb 12, 2014
Last update
Feb 12, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00606320
Responsible party
Sponsor
First posted
Feb 1, 2008
Start date
Jan 2008
Primary completion
Nov 2010
Completion
Nov 2010
Results posted
Feb 12, 2014
Last update
Feb 12, 2014

Study contacts

Katsuhisa Saito
study director · Department of Clinical Research and Development, Division of New Product Evaluation and Development

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aripiprazole

Start the discussion